DC瘤苗联合CIK姑息治疗广泛期小细胞肺癌的临床分析  

Clinical study of alleviative immunotherapy( autologous tumor antigen-loaded dendritic cell and cytokine-induced killer cell) on patients with extensive small cell lung cancer

作　　者：钟国成[1] 吴超群[2] 冯怀志[1] 胡俊梅[3] 刘建昆[4] 张明慧[1] 敬新蓉[1] 闵敏[1] 

机构地区：[1]解放军第452医院肿瘤科,四川成都610021 [2]解放军第452医院信息科,四川成都610021 [3]解放军第452医院麻醉科,四川成都610021 [4]成都军区昆明总医院消化科,云南昆明650032

出　　处：《现代肿瘤医学》2014年第11期2593-2596,共4页Journal of Modern Oncology

基　　金：四川省卫生厅科学研究项目(编号:050288)

摘　　要：目的:探讨负载同源肿瘤抗原(antigen,Ag)的树突状细胞(denritic cells,DC)联合细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)对广泛期小细胞肺癌(small cell lung cancer,SCLC)患者的临床姑息疗效。方法:选择120例诊断明确的广泛期SCLC患者(不再适宜行手术或放化疗),随机分为2组:对照组60例,接受内科姑息治疗;免疫组60例,除接受相同治疗外,还给予Ag-DC-CIK过继免疫治疗,记录2组患者的生活质量和疗效。结果:与对照组相比,细胞组患者的免疫功能增强,生活质量改善,临床疗效提高(P<0.05)。结论:Ag-DC-CIK过继免疫治疗对广泛期SCLC患者有较好的姑息治疗价值且安全可行。Objective：To study the clinical alleviative efficacy of autogenous tumor antigen（Ag）-pulsed dendritic cells（DC） in combination with cytokine-induced killer （CIK） cells on patients with extensive small cell lung cancer（SCLC）.Methods：All 120 patients with SCLC of extensive stage were randomly divided into two groups（all patients could not receive surgery,radiation or chemotherapy any more）.The control group of 60 patients received alleviative treatment only and the cellular group of 60 patients were treated by the method of adoptive immunotherapy （Ag-DC-CIK） combined with alleviative treatment.Results：After treatment,the immune functions,quality of life,survival time and curative effect in cellular group were much better than control group（P 〈0.05）.Conclusion：Ag-DC-CIK is an effective and safe alleviative treatment for patients with extensive SCLC.

关 键 词：肺肿瘤 小细胞肺癌 过继免疫 树突状细胞 细胞因子诱导杀伤细胞 

分 类 号：R734.2[医药卫生—肿瘤]